☰

Avery D. Posey, Ph.D. - Publications

Affiliations: 
2011 Genetics University of Chicago, Chicago, IL 
Area:
Molecular Biology, Cell Biology
Tree Info Similar researchers PubMed Report error

34 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, Haris M, Wilson NE, Liu F, Gabunia K, Scholler J, Montine TJ, Bhoj VG, Reddy R, Mohan S, ... ... Posey AD, et al. Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies. Cell. PMID 32961131 DOI: 10.1016/J.Cell.2020.08.022  0.307
2020 Guedan S, Madar A, Casado-Medrano V, Shaw CE, Wing A, Liu F, Young RM, June CH, Posey AD. Single residue in CD28-costimulated CAR T cells limits long-term persistence and antitumor durability. The Journal of Clinical Investigation. PMID 32069268 DOI: 10.1172/Jci133215  0.328
2020 Schwab RD, Bedoya DM, King TR, Levine BL, Posey AD. Approaches of T Cell Activation and Differentiation for CAR-T Cell Therapies. Methods in Molecular Biology (Clifton, N.J.). 2086: 203-211. PMID 31707678 DOI: 10.1007/978-1-0716-0146-4_15  0.306
2019 Ruella M, Barrett DM, Shestova O, Perazzelli J, Posey AD, Hong SJ, Kozlowski M, Lacey SF, Melenhorst JJ, June CH, Gill S. A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor positive cells. Blood. PMID 31703119 DOI: 10.1182/Blood.2019001859  0.345
2019 He Y, Schreiber K, Wolf SP, Wen F, Steentoft C, Zerweck J, Steiner M, Sharma P, Shepard HM, Posey A, June CH, Mandel U, Clausen H, Leisegang M, Meredith SC, et al. Multiple cancer-specific antigens are targeted by a chimeric antibody receptor on a single cancer cell. Jci Insight. 4. PMID 31672936 DOI: 10.1172/Jci.Insight.130416  0.317
2019 Migliorini D, Mason NJ, Posey AD. Keeping the Engine Running: The Relevance and Predictive Value of Preclinical Models for CAR-T Cell Development. Ilar Journal. PMID 31095687 DOI: 10.1093/Ilar/Ilz009  0.313
2019 Bedoya DM, King T, Posey A. Generation of CART cells targeting oncogenic TROP2 for the elimination of epithelial malignancies Cytotherapy. 21: S11-S12. DOI: 10.1016/J.Jcyt.2019.03.570  0.346
2019 King T, Posey A. Co-expression of an engineered cell-surface sialidase by CART cells improves anti-cancer activity of NK cells in solid tumors Cytotherapy. 21: S27. DOI: 10.1016/J.Jcyt.2019.03.338  0.31
2018 Watanabe K, Kuramitsu S, Posey AD, June CH. Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology. Frontiers in Immunology. 9: 2486. PMID 30416506 DOI: 10.3389/Fimmu.2018.02486  0.316
2018 Wing A, Fajardo CA, Posey AD, Shaw C, Da T, Young R, Alemany R, June CH, Guedan S. Improving CAR-T cell Therapy of solid tumors with Oncolytic Virus-driven Production of a Bispecific T-cell Engager. Cancer Immunology Research. PMID 29588319 DOI: 10.1158/2326-6066.Cir-17-0314  0.335
2018 Steentoft C, Migliorini D, King TR, Mandel U, June CH, Posey AD. GLYCAN-DIRECTED CAR-T CELLS. Glycobiology. PMID 29370379 DOI: 10.1093/Glycob/Cwy008  0.338
2018 Guedan S, Posey AD, Shaw C, Wing A, Da T, Patel PR, McGettigan SE, Casado-Medrano V, Kawalekar OU, Uribe-Herranz M, Song D, Melenhorst JJ, Lacey SF, Scholler J, Keith B, et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. Jci Insight. 3. PMID 29321369 DOI: 10.1172/Jci.Insight.96976  0.367
2017 Tchou J, Zhao Y, Levine BL, Zhang PJ, Davis MM, Melenhorst JJ, Kulikovskaya I, Brennan AL, Liu X, Lacey SF, Posey A, Williams AD, So A, Conejo-Garcia JR, Plesa G, et al. Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer. Cancer Immunology Research. PMID 29109077 DOI: 10.1158/2326-6066.Cir-17-0189  0.308
2017 Yin Y, Boesteanu A, Xu C, Posey A, Cook D, Blouch K, McGettigan-Croce B, Mason N, June CH, Lin Z, Johnson LA. Combinatorial IL13Rα2 chimeric antigen receptor-T cells plus checkpoint blockade to treat solid tumors in murine and canine models. Journal of Clinical Oncology. 35: 152-152. DOI: 10.1200/Jco.2017.35.7_Suppl.152  0.329
2016 Posey AD, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, Stone JD, Madsen TD, Schreiber K, Haines KM, Cogdill AP, Chen TJ, Song D, Scholler J, Kranz DM, et al. Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity. 44: 1444-1454. PMID 27332733 DOI: 10.1016/J.Immuni.2016.05.014  0.35
2016 Kawalekar OU, O'Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, Patel PR, Guedan S, Scholler J, Keith B, Snyder N, Blair I, Milone MC, June CH. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity. 44: 380-390. PMID 26885860 DOI: 10.1016/J.Immuni.2016.01.021  0.334
2016 Posey AD, Boestaneau A, Johnson LA, June CH. 510. Treating Epithelial and Metastatic Malignancies with Glycoform-Specific Chimeric Antigen Receptors Molecular Therapy. 24: S203-S204. DOI: 10.1016/S1525-0016(16)33319-6  0.312
2015 Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace AK, Dentchev T, Thekkat P, Loew A, Boesteanu AC, Cogdill AP, Chen T, Fraietta JA, Kloss CC, ... Posey AD, et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Science Translational Medicine. 7: 275ra22. PMID 25696001 DOI: 10.1126/Scitranslmed.Aaa4963  0.379
2015 Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, Kawalekar OU, Guedan S, McGettigan SE, Posey AD, Ang S, Cooper LJ, Platt JM, Johnson FB, Paulos CM, et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunology Research. 3: 356-67. PMID 25600436 DOI: 10.1158/2326-6066.Cir-14-0186  0.366
2015 Guedan S, Patel P, McGettigan SE, Posey AD, Kawalekar O, Scholler J, Keith B, June CH. 719. Combination of ICOS and 4-1BB in a Third Generation CAR Exhibits Enhanced T Cell Persistence and Increased Antitumor Effect Molecular Therapy. 23: S287. DOI: 10.1016/S1525-0016(16)34328-3  0.322
2015 Posey AD, Schwab RD, Boestaneau A, Johnson LA, June CH. 515. Targeting Hypoglycosylation with a Chimeric Antigen Receptor Molecular Therapy. 23: S206. DOI: 10.1016/S1525-0016(16)34124-7  0.344
2015 Posey AD, June CH. 211. CD2, the First Identified T cell Co-Stimulator, Demonstrates More Effective Chimeric Antigen Receptor Activity Over CD28 and 4-1BB Molecular Therapy. 23: S83. DOI: 10.1016/S1525-0016(16)33816-3  0.322
2014 Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace A, Thekkat P, Loew A, Chen TJ, Fraietta JA, Posey AD, Boesteanu AC, Cogdill AP, Engels B, et al. Pre-clinical validation of a humanized anti-EGFR variant III chimeric antigen receptor and phase I trial of CART-EGFRvIII in glioblastoma Journal For Immunotherapy of Cancer. 2: 1-1. PMID 25746013 DOI: 10.1186/2051-1426-2-S3-O1  0.351
2014 Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, Lee J, Posey AD, Scholler J, Scholler N, Bonneau R, June CH. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood. 124: 1070-80. PMID 24986688 DOI: 10.1182/Blood-2013-10-535245  0.336
2014 Posey AD, Swanson KE, Alvarez MG, Krishnan S, Earley JU, Band H, Pytel P, McNally EM, Demonbreun AR. EHD1 mediates vesicle trafficking required for normal muscle growth and transverse tubule development. Developmental Biology. 387: 179-90. PMID 24440153 DOI: 10.1016/J.Ydbio.2014.01.004  0.798
2014 Guedan S, McGettigan SE, Posey AD, Lee J, Kawalekar O, Patel PR, Keith B, June C. Enhancing T cell persistence of CAR-redirected T cells in solid tumors Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P244  0.32
2014 Kawalekar OU, O'Connor R, Guedan S, Fraietta J, Posey AD, Scholler J, Milone MC, June CH. Signaling Domain of Chimeric Antigen Receptors Can Reprogram T Cells Blood. 124: 551-551. DOI: 10.1182/Blood.V124.21.551.551  0.343
2014 Posey AD, Schwab RD, Boestaneau A, Johnson LA, June CH. Glycopeptide-Specific Chimeric Antigen Receptor Targeting of T Cell Leukemia Blood. 124: 4803-4803. DOI: 10.1182/Blood.V124.21.4803.4803  0.351
2013 Kawalekar OU, Posey AD, Fraietta J, Lee J, Scholler J, Zhao Y, June CH. Distinct Signaling By Chimeric Antigen Receptors (CARs) Containing CD28 Signaling Domain Versus 4-1BB In Primary Human T Cells Blood. 122: 2902-2902. DOI: 10.1182/Blood.V122.21.2902.2902  0.363
2011 Posey AD, Demonbreun A, McNally EM. Ferlin proteins in myoblast fusion and muscle growth. Current Topics in Developmental Biology. 96: 203-30. PMID 21621072 DOI: 10.1016/B978-0-12-385940-2.00008-5  0.794
2011 Posey AD, Pytel P, Gardikiotes K, Demonbreun AR, Rainey M, George M, Band H, McNally EM. Endocytic recycling proteins EHD1 and EHD2 interact with fer-1-like-5 (Fer1L5) and mediate myoblast fusion. The Journal of Biological Chemistry. 286: 7379-88. PMID 21177873 DOI: 10.1074/Jbc.M110.157222  0.768
2010 Demonbreun AR, Posey AD, Heretis K, Swaggart KA, Earley JU, Pytel P, McNally EM. Myoferlin is required for insulin-like growth factor response and muscle growth. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 24: 1284-95. PMID 20008164 DOI: 10.1096/Fj.09-136309  0.716
2008 Doherty KR, Demonbreun AR, Wallace GQ, Cave A, Posey AD, Heretis K, Pytel P, McNally EM. The endocytic recycling protein EHD2 interacts with myoferlin to regulate myoblast fusion. The Journal of Biological Chemistry. 283: 20252-60. PMID 18502764 DOI: 10.1074/Jbc.M802306200  0.68
2005 Doherty KR, Cave A, Davis DB, Delmonte AJ, Posey A, Earley JU, Hadhazy M, McNally EM. Normal myoblast fusion requires myoferlin. Development (Cambridge, England). 132: 5565-75. PMID 16280346 DOI: 10.1242/Dev.02155  0.699
Show low-probability matches.